Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1442)	3/22/2003 8:54:11 PM
From: microcapfun	Respond to of 3044

Thanks to both of you. By the way, here's a pretty good read, if you aren't already sick of reading about proteasome inhibition: >>Drug Discovery Today Volume 8, Issue 7 , 1 April 2003, Pages 307-315 Potential for proteasome inhibition in the treatment of cancer Julian Adams Millennium Pharmaceuticals, 35 Landsdowne Street, Cambridge, MA 02139, USA Available online 18 March 2003. Abstract Proteasome inhibition is a new approach to treating cancer. Proteasome inhibitors specifically induce apoptosis in cancer cells, but most proteasome inhibitors are not suitable for clinical development. Peptide boronates overcome the shortcomings of earlier generation proteasome inhibitors, and bortezomib (VELCADE™; formerly PS-341) is the first peptide boronate to enter clinical trials. Preclinical studies of bortezomib have demonstrated antitumor activity in a variety of tumor types. Phase I trials provided evidence of manageable toxicities and support a twice-weekly dosing regimen now being examined in a Phase III study. <<